Tag: desvenlafaxine

In June 2014, Arif Khan et al. published a trial of 361 patients randomised to three groups: abrupt versus 1-week taper versus no discontinuation of desvenlafaxine. Curiously, although all patients had depression, the readers were told that data on depressive symptoms “are reported elsewhere.”